PriceTargets.com logo

NASDAQ:SYRS - Syros Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.33
  • Forecasted Upside: 312.70 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$4.20 As of 10/22/2021 03:57 PM ET
▼ -0.12 (-2.78%)

This chart shows the closing price for SYRS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Syros Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SYRS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SYRS

Analyst Price Target is $17.33
▲ +312.70% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Syros Pharmaceuticals in the last 3 months. The average price target is $17.33, with a high forecast of $23.00 and a low forecast of $13.00. The average price target represents a 312.70% upside from the last price of $4.20.

This chart shows the closing price for SYRS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Syros Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/23/2021Roth CapitalBoost Price TargetBuy$20.00 ➝ $23.00Low
9/21/2021JMP SecuritiesReiterated RatingBuy$20.00High
8/6/2021JMP SecuritiesReiterated RatingBuyHigh
6/24/2021HC WainwrightReiterated RatingBuy$15.00Medium
5/30/2021JMP SecuritiesReiterated RatingBuyLow
3/5/2021Alliance Global PartnersLower Price Target$18.00 ➝ $14.00Low
11/10/2020Brookline Capital ManagementInitiated CoverageBuy$19.00Low
11/6/2020OppenheimerInitiated CoverageBuy$13.00High
11/4/2020HC WainwrightUpgradeNeutral ➝ Buy$11.00 ➝ $15.00High
10/26/2020Roth CapitalBoost Price TargetBuy$17.00 ➝ $20.00High
10/25/2020OppenheimerInitiated CoverageBuy$13.00High
9/22/2020Alliance Global PartnersInitiated CoverageBuy$18.00Medium
8/10/2020HC WainwrightReiterated RatingHold$11.00Medium
8/7/2020Piper SandlerBoost Price Target$14.00 ➝ $18.00Medium
8/6/2020JMP SecuritiesBoost Price TargetOutperform$16.00 ➝ $20.00Low
6/1/2020OppenheimerInitiated CoverageBuy$11.00Medium
5/29/2020Piper SandlerBoost Price TargetOverweight$12.00 ➝ $14.00Low
5/8/2020HC WainwrightReiterated RatingHoldHigh
5/7/2020OppenheimerReiterated RatingBuy$11.00High
3/6/2020HC WainwrightReiterated RatingNeutral$10.00 ➝ $8.00High
3/5/2020CowenReiterated RatingBuyHigh
1/17/2020WedbushDowngradeOutperform ➝ Neutral$9.00High
12/18/2019CowenReiterated RatingBuyHigh
11/13/2019HC WainwrightReiterated RatingHold$10.00High
11/12/2019CowenReiterated RatingBuyHigh
10/24/2019CowenReiterated RatingBuyLow
10/18/2019HC WainwrightSet Price TargetHold$10.00High
10/18/2019JMP SecuritiesLower Price TargetMarket Outperform$18.00 ➝ $16.00Medium
10/17/2019Piper Jaffray CompaniesLower Price Target$24.00 ➝ $18.00High
7/12/2019Roth CapitalInitiated CoverageBuy$17.00High
5/2/2019HC WainwrightReiterated RatingNeutralLow
4/25/2019WedbushReiterated RatingOutperform$13.00Low
4/10/2019Piper Jaffray CompaniesLower Price TargetOverweight$28.00 ➝ $24.00Low
3/8/2019Roth CapitalSet Price TargetBuy$14.00High
3/8/2019JMP SecuritiesReiterated RatingMkt Outperform ➝ Mkt Outperform$18.00High
3/8/2019HC WainwrightReiterated RatingHold$10.00High
3/7/2019OppenheimerSet Price TargetBuy$13.00High
2/14/2019OppenheimerReiterated RatingOutperform$13.00 ➝ $13.00Low
12/3/2018WedbushReiterated RatingOutperform$13.00High
12/2/2018Roth CapitalSet Price TargetBuy$14.00High
11/15/2018Roth CapitalSet Price TargetBuy$12.00Low
11/13/2018OppenheimerSet Price TargetBuy$26.00Low
11/5/2018Roth CapitalUpgradeNeutral ➝ Buy$12.00Medium
11/1/2018JMP SecuritiesSet Price TargetBuy$33.00High
11/1/2018OppenheimerSet Price TargetBuy$26.00Low
8/8/2018HC WainwrightReiterated RatingHold$10.00Low
7/17/2018CowenReiterated RatingBuyMedium
3/14/2018HC WainwrightReiterated RatingHold$10.00High
3/13/2018WedbushReiterated RatingOutperform ➝ Outperform$11.00 ➝ $13.00High
1/8/2018OppenheimerSet Price TargetBuy$28.00High
12/21/2017HC WainwrightReiterated RatingHold$10.00Low
12/13/2017OppenheimerSet Price TargetBuy$28.00Medium
12/11/2017CowenReiterated RatingBuyHigh
12/7/2017OppenheimerReiterated RatingBuy$28.00Low
10/31/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$30.00N/A
10/23/2017Roth CapitalInitiated CoverageNeutral ➝ Neutral$15.00N/A
9/28/2017JMP SecuritiesUpgradeMarket Perform ➝ Outperform$33.00High
8/10/2017WedbushReiterated RatingOutperform$25.00 ➝ $22.84Medium
8/10/2017JMP SecuritiesDowngradeOutperform ➝ Market PerformMedium
8/9/2017CowenReiterated RatingBuyHigh
6/12/2017OppenheimerSet Price TargetBuy$28.00High
5/16/2017WedbushReiterated RatingOutperform$22.00High
4/12/2017OppenheimerReiterated RatingOutperform$28.00Low
3/20/2017WedbushReiterated RatingOutperform$22.00 ➝ $18.00High
2/27/2017OppenheimerSet Price TargetBuy$28.00N/A
12/15/2016OppenheimerReiterated RatingBuy$28.00N/A
11/29/2016OppenheimerInitiated CoverageOutperform$28.00N/A
11/14/2016Piper Jaffray CompaniesSet Price TargetBuy$20.00N/A
11/14/2016WedbushReiterated RatingOutperform$18.00N/A
(Data available from 10/22/2016 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2021
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
9/22/2021
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/22/2021

Current Sentiment

  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Syros Pharmaceuticals logo
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $4.20
Low: $4.17
High: $4.30

50 Day Range

MA: $4.78
Low: $4.08
High: $5.55

52 Week Range

Now: $4.20
Low: $4.00
High: $15.65

Volume

10,951 shs

Average Volume

883,807 shs

Market Capitalization

$260.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.9

Frequently Asked Questions

What sell-side analysts currently cover shares of Syros Pharmaceuticals?

The following sell-side analysts have issued research reports on Syros Pharmaceuticals in the last twelve months: Alliance Global Partners, Brookline Capital Management, HC Wainwright, JMP Securities, Oppenheimer Holdings Inc., Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for SYRS.

What is the current price target for Syros Pharmaceuticals?

6 Wall Street analysts have set twelve-month price targets for Syros Pharmaceuticals in the last year. Their average twelve-month price target is $17.33, suggesting a possible upside of 301.2%. Roth Capital has the highest price target set, predicting SYRS will reach $23.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $13.00 for Syros Pharmaceuticals in the next year.
View the latest price targets for SYRS.

What is the current consensus analyst rating for Syros Pharmaceuticals?

Syros Pharmaceuticals currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SYRS will outperform the market and that investors should add to their positions of Syros Pharmaceuticals.
View the latest ratings for SYRS.

How do I contact Syros Pharmaceuticals' investor relations team?

Syros Pharmaceuticals' physical mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The company's listed phone number is (617) 744-1340 and its investor relations email address is [email protected] The official website for Syros Pharmaceuticals is www.syros.com.